Spots Global Cancer Trial Database for egfr inhibitor
Every month we try and update this database with for egfr inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC | NCT00492206 | Non Small Cell ... | Cetuximab | 18 Years - | University of Pittsburgh | |
| Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects | NCT02284139 | Non-small Cell ... Pancreatic Canc... Colorectal Canc... | Arm EGF ointmen... Arm EGF ointmen... Arm Placebos | 20 Years - | Dong-A University Hospital | |
| Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer | NCT00681967 | Head and Neck C... | Gefitinib Gefitinib | 18 Years - | AstraZeneca | |
| Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer | NCT00681967 | Head and Neck C... | Gefitinib Gefitinib | 18 Years - | AstraZeneca | |
| GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin | NCT00044343 | Colorectal Canc... | lapatinib | 18 Years - | GlaxoSmithKline | |
| Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) | NCT00788957 | Colon Cancer Colorectal Canc... Gastrointestina... Metastatic Colo... Rectal Cancer | Panitumumab Ganitumab Rilotumumab Placebo | 18 Years - | Amgen | |
| Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC | NCT02422628 | Lung Cancer | 20 Years - 85 Years | National Taiwan University Hospital | ||
| Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib | NCT00815971 | Non-Small Cell ... | 18 Years - | Aarhus University Hospital | ||
| Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects | NCT02284139 | Non-small Cell ... Pancreatic Canc... Colorectal Canc... | Arm EGF ointmen... Arm EGF ointmen... Arm Placebos | 20 Years - | Dong-A University Hospital | |
| Concentration and Activity of Lapatinib in Vestibular Schwannomas | NCT00863122 | Vestibular Schw... NF2 Neurofibromatos... Acoustic Neurom... Auditory Tumor | lapatinib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Concentration and Activity of Lapatinib in Vestibular Schwannomas | NCT00863122 | Vestibular Schw... NF2 Neurofibromatos... Acoustic Neurom... Auditory Tumor | lapatinib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Concentration and Activity of Lapatinib in Vestibular Schwannomas | NCT00863122 | Vestibular Schw... NF2 Neurofibromatos... Acoustic Neurom... Auditory Tumor | lapatinib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin | NCT00044343 | Colorectal Canc... | lapatinib | 18 Years - | GlaxoSmithKline | |
| Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone | NCT03040973 | Advanced Solid ... | Capmatinib Nazartinib Gefitinib Osimertinib | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
